Respiratory Disease Management with Inhaled Corticosteroids
Incidence and Risk Factors
- The incidence of pneumonia is higher with inhaled ICS-containing maintenance therapy, especially in individuals with severe and very severe disease, as acknowledged by the Canadian Thoracic Society guideline 1
- Adults with bronchiectasis and other chronic respiratory diseases who receive ICS have an increased risk of NTM infection and pneumonia, according to the European Respiratory Society guidelines 2
- Advanced age (70 years) is a significant risk factor for pneumonia in COPD patients on ICS therapy, as reported by the GOLD 2024 report 3
- Severe airflow obstruction (e.g., FEV1 of 45% predicted) significantly increases pneumonia risk with ICS use, as identified by guidelines from the European Respiratory Society and the American College of Chest Physicians 1, 4
Patient Risk Classification
- Patients can be classified into different risk levels for developing pneumonia when receiving ICS therapy based on factors such as age, BMI, FEV1, and comorbidities, with example risk levels including:
| Patient | Age | BMI | FEV1 | Comorbidities | Risk Level |
|---|---|---|---|---|---|
| Elderly male | 70 | Low | Severe obstruction | Hypertension | Highest Risk |
| Older female | 63 | Normal | Moderate obstruction | Heart failure | Moderate Risk |
| Middle-aged male | 53 | Normal | Moderate obstruction | One exacerbation | Moderate Risk |
| Younger female | 45 | Normal | Mild obstruction | Current smoker | Moderate Risk |
Harm and Benefit Analysis
- The number needed to harm (NNH) to cause one pneumonia is 33 patients for 1 year, according to the Canadian Thoracic Society guideline 1
- The combination of advanced age, low BMI, and severe airflow obstruction creates a high-risk profile for pneumonia in COPD patients on ICS therapy, although the specific guideline society is not specified in this case, the evidence is supported by multiple studies 5
Clinical Recommendations
- Clinicians should carefully assess pneumonia risk factors, particularly in elderly patients with low BMI and severe airflow obstruction, before initiating ICS therapy in COPD patients, as recommended by the American College of Chest Physicians 1
- For high-risk patients, consider LAMA/LABA combinations without ICS as initial therapy, as suggested by the American College of Chest Physicians 1
- If ICS therapy is necessary despite high pneumonia risk, implement close monitoring for respiratory infections 1
- Ensure pneumococcal and influenza vaccinations are up to date for all COPD patients, especially those on ICS therapy, as recommended by general guidelines for COPD patients 3, 1, 2